Clinical Trial Search

Primary: Tremor Amplitude — 127; 104; 150; 100 cm/s^2

Primary: Regions With fMRI Differences Between ET and Controls — 139; 93; 85; 74 Number of Activated Voxels

Primary: Change From Baseline to Week 4 in Maximum Angular Tremor Amplitude of the Wrist (Injected Limb) — -0.47; 0.07 degree — p=0.144

Primary: Change in Tremor Rating Scale (TRS) Compared With Baseline. — 2.4; -0.2; 6.7; 3.6 units on a scale

Primary: Change From Baseline Compared to Placebo in TETRAS Performance Subscale Part 4 Upper Limb Tremor Score on Day 29 — -2.31; -1.24 score on a scale — p=0.0491

Primary: Unilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist — -0.25; -0.46 degrees of arc

Primary: Stage 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 12.0; 20.0; 0; 0 percentage of participants

Primary: Difference in the 6 Week Post Injection Patient Global Impression of Improvement Scale (PGIS) Between Flexors Along and Flexors Plus Extensors Groups. — 1.2; 2.2 score…

Primary: Tremor Motor Score - Clinical Rating Scale for Tremor (CRST Part A (Upper Extremity) + Part B) Percent Change From Baseline — 46.9; -0.1 Percent Change from Baseline…

Primary: Normalized Accelerometric Tremor Power, Dominant Hand, 80min After Administration, Weighted Condition — 0.669; 0.798 ratio — p==0.345

Primary: Evaluate the Occurrence and Severity of Treatment Emergent AEs. — 13; 9; 2; 2 participants

Primary: Tremor Model Accuracy — 24; 21 Normalized RMSE (%)

Primary: Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale Item 4 (Upper Limb) Total Score on Day 91 in the Monotherapy Cohort…

Primary: Mean TRS (Tremor Rating Score) — 26.6; 27.6 units on a scale

Primary: Digital Spirography — 1.04; 1.00 millimeters of tremor amplitude

Primary: Change in Quality of Life in Essential Tremor (QUEST) Questionnaire Score — 39.41; 29.50; 23.60 units on a scale

Primary: Cognitive Assessment Using MoCA Version 7.1 Scores — 25.45; 27 units on a scale

Primary: Vocal Tremor Scoring System (VTSS) — 0.57; 0.57; 1; 0.43 units on a scale

Primary: Change From Baseline to Week 12 on the TETRAS Composite Outcome Score as Summarized by Each Dose of JZP385 and Placebo — -6.3; -5.8; -6.7; -7.5 score on a scale

Primary: Part A: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Upper Limb Score — -1.427; -2.912 Scores on a scale — p=0.1048

Primary: Change in Fullerton Advanced Balance (FAB) Scale Total Score After rTMS — 2.8; 0.9 change in score on a scale

Primary: Change in the MDS-UPDRS Tremor Subscore — 0.25; 0.27 score on a scale — p=0.5

Primary: Normalized Mean Tremor Amplitude for Both Formulations of 64 mg/kg 1-Octanol in Part B — 1; 1; 1.009; 0.901 normalized score on a scale

Primary: Clinical Rating Scale for Tremor (CRST) — 18.39534884; 13.97674419; 14.58139535 score on a scale — p=<0.01

Primary: Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor — 12.91; 13.49; 12.43; 9.35 percentage of voice signal with tremor — p=0.0216

Primary: Percent Change in Tremor Power — 43; 9 percent tremor improvement

Primary: Fugl-Meyer Assessment of the Upper Extremity — 4.08; 2.45 score on a scale — p=0.912

Primary: Number of Device and Procedure Related Adverse Events. — 121 Number of adverse events

Primary: Part A: Change From Baseline in Accelerometer-based Kinesia Kinetic Tremor Combined Score at Day 7 — 4.36; -0.69 score on a scale

Primary: Baseline and Day 28 on The Essential Tremor Rating Assessment Scale Performance Subscale (TETRAS-PS) Total Score — 22.7; 22.8; 21.1; 20.7 score on a scale